Ingenol Mebutate: A Succinct Review of a Succinct Therapy

被引：26

作者：

Alchin D.R. ^{[1
]}

机构：

[1] The University of Melbourne, Parkville

来源：

Dermatology and Therapy | 2014年 / 4卷 / 2期

关键词：

Actinic keratosis; Dermatology; Field therapy; Ingenol; 3-angelate; Ingenol mebutate; Picato; Solar keratosis; Squamous cell carcinoma;

D O I：

10.1007/s13555-014-0061-2

中图分类号：

学科分类号：

摘要：

Background: Ingenol mebutate is a newly approved topical field therapy for actinic keratosis (AK). It has a dual mechanism of action comprising of a rapid induction of necrosis that specifically targets dysplastic cells, as well as neutrophil-mediated immunostimulatory effects. Such a dual mechanism allows for this agent to clear AK lesions in as little as two to three daily applications, thus providing for improved treatment outcomes and patient satisfaction.; Review: Given that this is a new dermatologic therapy, this review summarizes the key literature surrounding this agent. This review covers the indications for use, mechanisms of action, method of administration, efficacy and safety profile and important drug interactions of ingenol mebutate.; Conclusions: Ingenol mebutate should be considered a highly relevant field therapy for AK and the prevention of progression to squamous cell carcinoma. © 2014, The Author(s).

引用

页码：157 / 164

页数：8

共 20 条

[11]

Rosen R.H., Gupta A.K., Tyring S.K., Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response, J Am Acad Dermatol, 66, 3, pp. 486-493, (2012)

[12]

Samrao A., Cockerell C.J., Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents, Am J Clin Dermatol, 14, 4, pp. 273-277, (2013)

[13]

Fidler B., Goldberg T., Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses, Pharm Ther, 39, 1, pp. 40-46, (2014)

[14]

Stahlhut M., Bertelsen M., Hoyer-Hansen M., Svendsen N., Eriksson A.H., Lord J.M., Et al., Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells, JDD, 11, 10, pp. 1181-1192, (2012)

[15]

Ersvaer E., Kittang A.O., Hampson P., Sand K., Gjertsen B.T., Lord J.M., Et al., The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity, Toxins, 2, 1, pp. 174-194, (2010)

[16]

Fallen R.S., Gooderham M., Ingenol mebutate: an introduction, Skin Ther Lett, 17, 2, pp. 1-3, (2012)

[17]

Siller G., Gebauer K., Welburn P., Katsamas J., Ogbourne S.M., PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study, Australas J Dermatol, 50, 1, pp. 16-22, (2009)

[18]

Lebwohl M., Swanson N., Anderson L.L., Melgaard A., Xu Z., Berman B., Ingenol mebutate gel for actinic keratosis, New Engl J Med, 366, 11, pp. 1010-1019, (2012)

[19]

Dosik J.S., Damstra M., Udell C., Welburn P., Evaluation of the skin sensitization, photo irritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers, J Clin Aesthet Dermatol, 7, 4, pp. 35-42, (2014)

[20]

Martin G., Swanson N., Clinical findings using ingenol mebutate gel to treat actinic keratoses, J Am Acad Dermatol, 68, 1, pp. S39-S48, (2013)

← 1 2 →